J Am Vet Med Assoc. 2022 Sep 1;260(14):1827-1833. doi: 10.2460/javma.21.11.0498.
To evaluate the efficacy of doxorubicin for treatment of histiocytic sarcoma (HS) in dogs, whether administered as the sole treatment or as an adjunct to surgery or radiation therapy.
31 client-owned dogs with localized or disseminated HS examined between 2003 and 2017.
Medical records were reviewed retrospectively, and data were collected. The Kaplan-Meier method was used to estimate time-to-progression from the date of first doxorubicin administration and survival time from initial diagnosis. Factors that could be associated with poorer outcomes with doxorubicin treatment were analyzed with log-rank tests.
The objective response rate (ORR) was 26%. When stratified by disease status, dogs with localized and disseminated forms experienced 43% and 21% ORRs, respectively. Median time to progression after initiating doxorubicin treatment (n = 30 dogs) was 42 days. Median survival time from initial diagnosis to death (n = 29 dogs) was 169 days. Complete responses were obtained in only 2 dogs that had localized disease and received multimodality therapy.
Benefits of doxorubicin administration in canine HS are modest, with a limited ORR and delay in tumor progression, and are comparable to effects attained with other single-agent regimens.
评估多柔比星治疗犬Histiocytic Sarcoma（HS）的疗效，无论其作为单一治疗方法还是作为手术或放射治疗的辅助手段。
2003 年至 2017 年间检查的 31 只患有局限性或播散性 HS 的患犬。
回顾性审查病历并收集数据。采用 Kaplan-Meier 法估计从首次多柔比星给药日期到进展时间和从初始诊断到死亡时间的生存时间。用对数秩检验分析与多柔比星治疗预后较差相关的因素。
客观缓解率（ORR）为 26%。按疾病状态分层，局限性和播散性疾病的犬 ORR 分别为 43%和 21%。开始多柔比星治疗后进展的中位时间（n = 30 只犬）为 42 天。从初始诊断到死亡的中位生存时间（n = 29 只犬）为 169 天。仅 2 只患有局限性疾病并接受多模式治疗的犬获得完全缓解。
多柔比星在犬 HS 中的应用的益处有限，ORR 有限且肿瘤进展延迟，与其他单药治疗方案的效果相当。
